USPTO serial 79402827
EVERDIUM
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 4, 2025
- Examiner
- MICKLEBURGH, LINDA BOHANNON
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with EVERDIUM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jeremy Blackowicz
Jeremy Blackowicz Bausch Health Companies400 Somerset Corporate Blvd.Bridgewater, NJ 08807United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Non-medicated skin care preparations; non-medicated oral care preparations, namely, toothpaste, mouthwash, dental rinse; oral hygiene preparations, namely, toothpaste, mouthwash, dental rinse; cosmetics | ACTIVE | — |
| 005 | Pharmaceutical products and medicines for human use for the prevention and treatment of allergies; Pharmaceutical products and medicines for human use for the prevention and treatment of autoimmune conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of blood conditions, diseases and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of cardiovascular diseases and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of conditions, diseases, and disorders of the central and peripheral nervous system; Pharmaceutical products and medicines for human use for the prevention and treatment of dermatological conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of endocrine conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of gastrointestinal conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of hepatic conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of immunological conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of infectious diseases; Pharmaceutical products and medicines for human use for the prevention and treatment of inflammatory conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of metabolic conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of neurological conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of pain; Pharmaceutical products and medicines for human use for the prevention and treatment of psychiatric conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of respiratory and pulmonary conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of renal conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of urological conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of viral diseases; Pharmaceutical products and medicines for human use, namely, antibiotics; Pharmaceutical products and medicines for human use, namely, medicated beverages, powders, and gels for colonoscopies and endoscopic procedures; medicated skin care preparations; medicated oral care preparations, namely mouthwash, dental rinses; nutritional supplements; dietary supplements; vitamins; diagnostic preparations for medical purposes | ACTIVE | — |
| 010 | Surgical apparatus and instruments; medical apparatus for the delivery and release of pharmaceuticals, namely, drug delivery patches sold without medication, inhalers for medical use sold empty, intravenous bags sold empty for intravenous therapy, syringes; medical apparatus for facilitating the inhalation of pharmaceutical preparations; medical apparatus for the treatment of respiratory conditions; medical diagnostic apparatus for medical purposes for testing of blood sugar levels, respiratory health, liver function, kidney function, viruses, cancer cells, DNA, antibody levels; medical devices for non-surgical cosmetic skin treatments; lasers for the medical and cosmetic treatment of the face and skin; radiofrequency apparatus for the medical and cosmetic treatment of the face and skin; high frequency electromagnetic wave therapeutic instruments; medical devices and equipment for liposuction; apparatus for the treatment of cellulite; medical apparatus and instruments using radiofrequency energy for body toning and body shaping; apparatus for non-invasive surgery, namely for body toning and body shaping; medical apparatus generating electromagnetic, magnetic, electrical, mechanical or thermal energy for the therapeutic stimulation of the body | ACTIVE | — |
| 042 | Pharmaceutical research and development; research and development services relating to medicines; conducting clinical trials for others for pharmaceutical products; testing of pharmaceuticals; medical and scientific research and analysis for the prevention, diagnosis, treatment and management of illness and disease; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; conducting early evaluations in the field of new pharmaceuticals; pharmaceutical drug delivery system development services; product research and development in the field of beauty, wellness, and health care products | ACTIVE | — |
| 044 | Providing medical information; providing health information; consultancy and medical information services relating to medical products; providing medical and health information and treatment support programs to consumers and healthcare professionals regarding pharmaceutical products; medical services, namely, providing medical information regarding prescription drugs and disease prevention, diagnosis, screening, and treatment; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; providing medical and health information in the field of illness and disease prevention, screening, diagnosis, and treatment; providing medical and health information and treatment support programs to consumers and healthcare professionals regarding medical aesthetics treatments and procedures; providing medical and health information to consumers and healthcare professionals regarding dental treatment, dental hygiene, and oral health; medical testing services relating to the diagnosis and treatment of illness and disease; providing information in the fields of health and wellness; cosmetic facial and body treatment services; non-invasive cosmetic medical services; aesthetic and therapeutic skin and body treatment services; laser skin rejuvenation service; laser skin tightening service; medical treatment services, namely energy-based procedures for treatment of the face, body, tissue and skin | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Bausch Health Ireland Limited
- Other trademarks owned by Bausch Health Ireland Limited
- Other trademarks owned by Bausch Health Ireland Limited
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named EVERDIUM
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 5, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 21, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 21, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 5, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 19, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 19, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 5, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 4, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Feb 4, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 17, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 17, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 11, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 23, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 22, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 20, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 20, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 19, 2024 | ALIE | ASSIGNED TO LIE | — |
| Nov 19, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 19, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 19, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 8, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 8, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 8, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 1, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 8, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 8, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 3, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 2, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 26, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 6, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 6, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 22, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |